Document is current
Any future updates will be listed below
-
Authors
Ferle, Maximilian
Ader, Jonas
Wiemers, Thomas
Grieb, Nora
Berneck, Beatrice
Lindenmeyer, Adrian
Goldschmidt, Hartmut
Mai, Elias K.
Bertsch, Uta
Meyer, Hans-Jonas
Neumuth, Thomas
Kreuz, Markus
Reiche, Kristin
Merz, Maximilian
-
Funding
Funding for this research was provided by:
European Union (CERTAINTY)
European Union (CERTAINTY)
European Union (CERTAINTY)
Sächsisches Staatsministerium für Wissenschaft, Kultur und Tourismus (ScaDS.AI)
Sächsisches Staatsministerium für Wissenschaft, Kultur und Tourismus (ScaDS.AI)
International Myeloma Society (IMS Research Grant 2023)
International Myeloma Society (IMS Research Grant 2023)
German Research Foundation (SPP µbone)
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 12 April 2026
First Online: 11 May 2026
Competing interests
: MM received financial support from and/or held consulting or advisory roles for SpringWorks Therapeutics Inc., Janssen-Cilag GmbH and Roche Deutschland Holding GmbH. HG received financial support from and/or held consulting or advisory roles for Janssen-Cilag GmbH, Celgene GmbH, Novartis Pharma GmbH, Onyx Pharmaceuticals Inc, Takeda Pharma Vertrieb GmbH and Roche Deutschland Holding GmbH. EKM received financial support from and/or held consulting or advisory roles for Amgen GmbH, Bristol Myers Squibb GmbH, GlaxoSmithKline GmbH, Janssen-Cilag GmbH, Oncopeptides GmbH, Pfizer Deutschland GmbH, Sanofi-Aventis Deutschland GmbH, Stemline Therapeutics GmbH and Takeda Pharma Vertrieb GmbH. MF, JA, TW, NG, BB, AL, HJM, TN, MK and KR declare no conflict of interest.
